The impact of tumor size change after target therapy on survival: Analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 349-355

  Zhang, Jianwei ^a   Huang, Yan ^a   Li, Xiaoling ^a   Guo, Ying ^a   Zhao, Yuanyuan ^a   Xue, Cong ^a   Hu, Zhihuang ^a   Zhang, Li ^a   Zhao, Hongyun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Non small cell lung cancer; Prognostic factor; Stable disease; Target therapy

Indexed keywords

ERLOTINIB; GEFITINIB; VANDETANIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPLETE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL RESPONSE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR CRITERIA; RETROSPECTIVE STUDY; SMOKING; STABLE DISEASE; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME;

EID: 84873924744     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S38441     Document Type: Article

References (19)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49(1):8-31.
2. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park). 2003;17(3):357-364.
3. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98.
4. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 2012;13(5):247-263.
5. Mountzios G, Owonikoko T, Karamouzis M, Argiris A. Current and emerging roles of epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer. The Open Lung Cancer Journal. 2010; 310(57):57-65.
6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
7. Sarkar S, Mazumdar A, Dash R, Sakar D, Fisher PB, Mandal M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther. 2010;9(8):592-603.
8. Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol. 2003;21(11):2094-2100.
9. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2): 123-132.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
11. Kurata T, Matsuo K, Takada M, et al. Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? J Thorac Oncol. 2006;1(7):684-691.
12. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
14. Zhao YY, Zhang Y, Zhao HY, et al. Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials. CJC. 2009;28(6):626-631. Chinese.
15. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial). J Clin Oncol. 2003;21(12):2237-2246.
16. Sirohi B, Ashley S, Norton A, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol. 2007;2(8):735-740.
17. Yamamoto N, Nishiwaki Y, Negoro S, et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients. J Thoracic Oncology. 2010;5(7):1042-1047.
18. Kris MG. Foreword; challenging the 'one-size-fts-all' approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer. Lung Cancer. 2008;60 Suppl 2:S1-S2.
19. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No 48. Geneva: World Health Organization; 1979. Available from: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf. Accessed October 18, 2012.